746 related articles for article (PubMed ID: 33471574)
1. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
3. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
[TBL] [Abstract][Full Text] [Related]
4. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
[TBL] [Abstract][Full Text] [Related]
5. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.
Schrag D; Uno H; Rosovsky R; Rutherford C; Sanfilippo K; Villano JL; Drescher M; Jayaram N; Holmes C; Feldman L; Zattra O; Farrar-Muir H; Cronin C; Basch E; Weiss A; Connors JM;
JAMA; 2023 Jun; 329(22):1924-1933. PubMed ID: 37266947
[TBL] [Abstract][Full Text] [Related]
6. Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials.
Brunetti ND; Tricarico L; Correale M; De Gennaro L; Santoro F; Ieva R; Di Biase M
J Thromb Thrombolysis; 2020 Aug; 50(2):305-310. PubMed ID: 31654194
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
8. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
Kirkilesis GI; Kakkos SK; Tsolakis IA
Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
[TBL] [Abstract][Full Text] [Related]
11. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis.
Giustozzi M; Agnelli G; Del Toro-Cervera J; Klok FA; Rosovsky RP; Martin AC; Herold J; Tzoran I; Szmit S; Bertoletti L; Becattini C; Huisman MV
Thromb Haemost; 2020 Jul; 120(7):1128-1136. PubMed ID: 32365386
[TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
Li A; Garcia DA; Lyman GH; Carrier M
Thromb Res; 2019 Jan; 173():158-163. PubMed ID: 29506866
[TBL] [Abstract][Full Text] [Related]
13. Management patterns and outcomes in symptomatic venous thromboembolism following allogeneic hematopoietic stem cell transplantation. A 15-years experience at a single center.
Labrador J; González-Rivero J; Monroy R; Lozano FS; López-Corral L; Caballero MD; Bastida JM; González-Porras JR
Thromb Res; 2016 Jun; 142():52-6. PubMed ID: 26922092
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
[TBL] [Abstract][Full Text] [Related]
15. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants.
Uppuluri EM; Burke KR; Haaf CM; Shapiro NL
J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721
[TBL] [Abstract][Full Text] [Related]
16. Decreased Bleeding Incidence with Direct Oral Anticoagulants Compared to Vitamin K Antagonist and Low-Molecular-Weight Heparin in Patients with Sickle Cell Disease and Venous Thromboembolism.
Patel A; Williams H; Baer MR; Zimrin AB; Law JY
Acta Haematol; 2019; 142(4):233-238. PubMed ID: 31108496
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
18. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.
van der Wall SJ; Klok FA; den Exter PL; Barrios D; Morillo R; Cannegieter SC; Jimenez D; Huisman MV
J Thromb Haemost; 2017 Jan; 15(1):74-79. PubMed ID: 28012224
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
[TBL] [Abstract][Full Text] [Related]
20. Operative spinal trauma: Thromboprophylaxis with low molecular weight heparin or a direct oral anticoagulant.
Hamidi M; Zeeshan M; Kulvatunyou N; Mitra HS; Hanna K; Tang A; Northcutt A; O'Keeffe T; Joseph B
J Thromb Haemost; 2019 Jun; 17(6):925-933. PubMed ID: 30924300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]